Vol. 6, Issue 1, Part A (2024)

Double blinded randomized controlled clinical trial carried out in gynecological and obstetric department in Tikrit Teaching Hospital from 1st October 2023 to 28th July 2024. A sample of 100 women candidates for intrauterine device insertion was enrolled in the study; divided randomly into 2 groups; group A (50 women) received 400 microgram of misoprostol vaginally 3 hours before intrauterine device insertion and group B (50 women) as a control group. 
Most of the cases and control group had ≥2 caesarian section (c/s) 26(52%), 32(64%) respectively. In most of the cases group and control group the uterine position was anteverted uterus (AVU), 48(96%), 49(98%) respectively, while retroverted uterus (RVU) found among 2(4%) of the cases and 1(2%) of the controls, this relation was statistically not significant, Failed insertion significantly lower among cases 1(2%) than controls 2(4%), the easy insertion was significantly higher among cases 35 (70%) than controls 23(46%), while difficult insertion was significantly lower among cases 14(28%) than controls 25(50%). The mean visual analogue scale (VAS) scores of cases group (3.4±0.7) was significantly lower than control group (5.3±0.8). The mean patient satisfaction score of cases group (9.1±0.5) was significantly higher than control group (7.8±0.6). Non-significant difference in analgesia needed among cases group 6(12%) and control group 13(26%) of the. The commonest side effect reported among cases was abdominal cramping 10(20%), was significantly higher than control group 3(6%), followed by diarrhea 7(14%), 0(0%) respectively, and nausea 7(14%), 1(2%) respectively.